FOXO4-DRI retains residual kill under Bax/Bak LOF that abolishes navitoclax
STATUS_LABEL: NEGATIVE
Claim
On a matched senescent culture where Bax/Bak loss-of-function (or BAX-channel blockade) abolishes navitoclax senescent-cell kill (pre-registered navitoclax residual kill under LOF ≤20% of control-genotype navitoclax kill, or outside a pre-registered abolish band), FOXO4-DRI retains measurable residual SC kill — FOXO4-DRI kill under the same LOF ≥20% of its control-genotype FOXO4-DRI kill (or outside a pre-registered null-residual band).
Why it matters
Complement of P7’s “≥ equal abolish”: if FOXO4–p53 entry can still execute via Bax-independent routes when Bcl-2-family senolytics are fully gated, pathway identity is not full MOMP-execution identity. P5–P7 left matched epistasis UNKNOWN and only flagged residual Bax-independence as a limitation; they are not proof of residual kill. Soft-claims: discussion — FOXO4-DRI∩Bax residual/epistasis soft-complete 0; residual panel remains UNKNOWN.
Mechanism sketch
FOXO4-DRI enters via FOXO4–p53; navitoclax via Bcl-2/Bcl-xL/Bcl-w; both may still require Bax/Bak MOMP for execution — or FOXO4-DRI may keep partial Bax-independent death routes once navitoclax is fully gated. Endothelial FOXO4-DRI work frames a p53 / BCL-2 / Caspase-3 cascade without a Bax/Bak LOF residual-kill panel. Humanin–Bax MOMP block is mechanism prior for BAX-channel tools, not a FOXO4-DRI residual result. Assumption-kill of full MOMP-execution identity: residual FOXO4-DRI under LOF that abolishes navitoclax means distinct entry is not full execution identity.
Prior art
- PMID 28340339 / DOI 10.1016/j.cell.2017.02.031 / PMC5556182 — FOXO4-DRI perturbs FOXO4–p53 → senescent-cell apoptosis (Baar 2017); not Bcl-xL occupancy; no Bax/Bak LOF residual arm.
- PMID 41625068 / DOI 10.3389/fbioe.2025.1729166 / PMC12852416 — endothelial FOXO4-DRI framed via p53 / BCL-2 / Caspase-3 (2025); BCL-2/caspase cascade ≠ Bax/Bak LOF residual panel.
- PMID 26711051 / DOI 10.1111/acel.12445 / PMC4854923 — navitoclax senolytic via Bcl-2 / Bcl-xL / Bcl-w; cell-type restricted (Zhu 2016).
- PMID 12732850 / DOI 10.1038/nature01627 — humanin binds Bax; blocks mitochondrial translocation / cytochrome c release (Guo 2003) — MOMP-block prior, not FOXO4-DRI residual under LOF.
Baseline claimed
Under Bax/Bak LOF that abolishes navitoclax SC kill, FOXO4-DRI retains measurable residual SC kill on the same culture (or P7’s ≥ equal abolish / residual-limitation already settles residual independence).
Baseline measured
FOXO4–p53 entry LITERATURE (PMID 28340339). Downstream BCL-2/caspase framing LITERATURE without Bax/Bak LOF residual (PMID 41625068). Navitoclax Bcl-2-family senolytic LITERATURE (PMID 26711051). HN–Bax MOMP block LITERATURE as mechanism prior (PMID 12732850). Matched Bax/Bak LOF (abolishing navitoclax) × residual FOXO4-DRI SC kill UNKNOWN (soft-complete 0). Residual ≥20% of control-genotype FOXO4-DRI kill under LOF that abolishes navitoclax PREDICTION. P5–P7 do not already prove this residual.
Actionable limitations
- Do not treat P5/P6/P7 as proving P8 — P7 left matched epistasis UNKNOWN and only flagged residual Bax-independence as a limitation; empty soft-complete ≠ demonstrated residual kill.
- Gating condition is strong — assay requires LOF that abolishes the navitoclax arm first; partial navitoclax resistance misreads as FOXO4-DRI residual.
- BCL-2 cascade ≠ Bax residual — 41625068 implicates BCL-2/caspase nodes without genetic Bax/Bak necessity or residual measurement; alternate death routes remain PREDICTION until scored under the same LOF.
Method
propose-assay
Prediction variables
| name | kind | assay | threshold |
|---|---|---|---|
| FOXO4_DRI_p53_entry | LITERATURE | FOXO4 peptide disrupts FOXO4–p53 in senescent cells → apoptosis (Baar 2017) | FOXO4–p53 axis entry, not Bcl-xL occupancy (PMID 28340339) |
| FOXO4_DRI_p53_BCL2_Caspase3_framing | LITERATURE | Senescent endothelium FOXO4-DRI via p53/BCL-2/Caspase-3 (2025) | mitochondrial Bcl-2-family nodes may sit downstream (PMID 41625068) — not Bax/Bak LOF residual |
| navitoclax_Bcl2_family_senolytic | LITERATURE | ABT-263 senolysis in restricted SC panels (Zhu 2016) | Bcl-2/Bcl-xL/Bcl-w dependent; cell-type restricted (PMID 26711051) |
| HN_Bax_MOMP_block_mechanism_prior | LITERATURE | HN–Bax binding; blocks Bax translocation / cytochrome c (Guo 2003) | MOMP / cytochrome c suppression (PMID 12732850) — prior for BAX tools; not FOXO4-DRI residual; no KD invented |
| matched_BaxBak_LOF_residual_FOXO4_panel | UNKNOWN | Same culture — Bax/Bak LOF or BAX-channel block × FOXO4-DRI vs navitoclax; require navitoclax abolish, then score FOXO4-DRI residual | dedicated residual LOF panel not found (soft-complete 0) — UNKNOWN |
| FOXO4_residual_under_LOF_that_abolishes_navitoclax | PREDICTION | Pre-registered matched culture; LOF abolishes navitoclax first, then score FOXO4-DRI residual | navitoclax under LOF ≤20% of control-genotype AND FOXO4-DRI under LOF ≥20% of control-genotype; α/N pre-specified — no invented % or dosing |
| competing_partial_navitoclax_gate_misread | PREDICTION | Same design; falsifier if apparent residual coincides with incomplete navitoclax abolish | incomplete navitoclax gate = pre-registered competing / QC fail |
Ablate
- remove matched Bax/Bak LOF panel that first abolishes navitoclax, then scores FOXO4-DRI residual: Without the gated residual panel, separate LITERATURE legs cannot show FOXO4-DRI retains kill when navitoclax is fully Bax/Bak-gated.
- remove navitoclax-abolish gating condition: Without requiring navitoclax abolish first, partial resistance misreads as FOXO4-DRI residual.
- remove P5–P7≠proof + soft-complete-empty≠residual + BCL-2-framing≠Bax-residual discipline: Treating P7 or empty PubMed as already deciding residual independence would invent a result left UNKNOWN.
Refute if
On the pre-registered matched panel where Bax/Bak LOF / BAX-channel block abolishes navitoclax kill, FOXO4-DRI residual kill also falls inside the null-residual band (FOXO4-DRI kill under LOF <20% of control-genotype, or inside band) — full MOMP-execution identity / ≥ equal abolish survives and residual Bax-independence fails.
Ask a human
Lock one senescent system sensitive to both senolytics, Bax/Bak LOF vs BAX-channel-block tool, navitoclax-abolish QC, and viability + cytochrome-c readout before claiming residual FOXO4-DRI under LOF; do not treat P5–P7 as proof; no dosing.
Cheap IP
kill_cost_tier=1 · time_to_refute=4w · ip_class=momp-execution-gate · vault_hold=no
Execution
execution_status=NOT_RUN · fto_status=UNKNOWN · related_prior=P7 (not proof of residual FOXO4-DRI under LOF)